A randomized controlled trial of intranasal ketamine in migraine with prolonged aura

Conclusions: These data provide translational evidence for the potential importance of glutamatergic mechanisms in migraine aura and offer a pharmacologic parallel between animal experimental work on cortical spreading depression and the clinical problem. Classification of evidence: This study provides Class III evidence that intranasal ketamine is effective in reducing aura severity in patients with migraine with prolonged aura.

http://www.neurology.org/cgi/content/short/80/7/642?rss=1

Source: Neurology - February 11, 2013 Category: Neurology Authors: Afridi, S. K., Giffin, N. J., Kaube, H., Goadsby, P. J. Tags: Migraine, Clinical trials Randomized controlled (CONSORT agreement), Class III ARTICLE Source Type: research